Literature DB >> 25194449

Symptomatic remission and patient quality of life in an observational study of schizophrenia: is there a relationship?

Josep M Haro1, Diego Novick2, Elena Perrin3, Jordan Bertsch4, Martin Knapp5.   

Abstract

This analysis aimed to examine the association between remission and quality of life (QOL) in schizophrenia. In post-hoc analyses of the 3-year, prospective, observational Schizophrenia Outpatients Health Outcomes (SOHO) study, we compared the QOL of patients who achieved symptomatic and clinical remission with those who did not, and the factors associated. Symptomatic remission was defined as achieving a score of ≤3 on the Clinical Global Impression-Schizophrenia (CGI-SCH) scale, maintained for 6 months and without hospitalization. QOL was patient self-rated using the European-QOL. Of the 6516 patients analyzed, 38% were in symptomatic remission 12 months post-baseline and 52% at 36 months. Functional remission remained fairly constant from 12 months to 36 months (22.4% at both time points). At all visits from 12 to 36 months, patient QOL and social functioning were significantly higher for patients in symptomatic remission. QOL was higher in patients in functional remission. Patients with maintained symptomatic remission over the 3-year follow-up had a much greater improvement in QOL than patients with no symptomatic remission or symptomatic remission for part of the period. Factors associated with a better QOL also included paid employment, socially active, a higher CGI-SCH cognitive score, good compliance, and a better baseline QOL.
Copyright © 2014. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Observational study; Quality of life; Remission; Schizophrenia

Mesh:

Year:  2014        PMID: 25194449     DOI: 10.1016/j.psychres.2014.07.034

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

1.  Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year Study.

Authors:  Julien Dubreucq; Franck Gabayet; Ophélia Godin; Myrtille Andre; Bruno Aouizerate; Delphine Capdevielle; Isabelle Chereau; Julie Clauss-Kobayashi; Nathalie Coulon; Thierry D'Amato; Jean-Michel Dorey; Caroline Dubertret; Mégane Faraldo; Hakim Laouamri; Sylvain Leigner; Christophe Lancon; Marion Leboyer; Pierre-Michel Llorca; Jasmina Mallet; David Misdrahi; Christine Passerieux; Romain Rey; Baptiste Pignon; Benoit Schorr; Mathieu Urbach; Franck Schürhoff; Andrei Szoke; Guillaume Fond; Fabrice Berna
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 9.306

2.  Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study.

Authors:  Merhawi Bahta; Tzeggai Berhe; Mulugeta Russom; Eyasu H Tesfamariam; Azieb Ogbaghebriel
Journal:  Integr Pharm Res Pract       Date:  2020-10-14

3.  Lack of tolerable treatment options for patients with schizophrenia.

Authors:  Leslie Citrome; Anna Eramo; Clement Francois; Ruth Duffy; Susan N Legacy; Steve J Offord; Holly B Krasa; Stephen S Johnston; Alice Guiraud-Diawara; Siddhesh A Kamat; Patricia Rohman
Journal:  Neuropsychiatr Dis Treat       Date:  2015-12-16       Impact factor: 2.570

4.  Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.

Authors:  George Awad; Daisy Ng-Mak; Krithika Rajagopalan; Jay Hsu; Andrei Pikalov; Antony Loebel
Journal:  BMC Psychiatry       Date:  2016-06-01       Impact factor: 3.630

Review 5.  Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode.

Authors:  Dolores Keating; Stephen McWilliams; Ian Schneider; Caroline Hynes; Gráinne Cousins; Judith Strawbridge; Mary Clarke
Journal:  BMJ Open       Date:  2017-01-06       Impact factor: 2.692

6.  Service-user efforts to maintain their wellbeing during and after successful withdrawal from antipsychotic medication.

Authors:  Miriam Larsen-Barr; Fred Seymour
Journal:  Ther Adv Psychopharmacol       Date:  2021-01-31

7.  Investigating the Role of Insight, Decision-Making and Mentalizing in Functional Outcome in Schizophrenia: A Cross-Sectional Study.

Authors:  Paula Jhoana Escobedo-Aedo; Ana Forjan-González; Adela Sánchez-Escribano Martínez; Verónica González Ruiz-Ruano; Sergio Sánchez-Alonso; Laura Mata-Iturralde; Laura Muñoz-Lorenzo; Enrique Baca-García; Anthony S David; Javier-David Lopez-Morinigo
Journal:  Behav Sci (Basel)       Date:  2022-01-27

8.  Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes.

Authors:  Katalin Pungor; Vasilis P Bozikas; Robin Emsley; Pierre-Michel Llorca; Srihari Gopal; Maju Mathews; Annette Wooller; Paul Bergmans
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-23

9.  Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia.

Authors:  Maria Paz Garcia-Portilla; Pierre-Michel Llorca; Giuseppe Maina; Vasilis P Bozikas; Halise Devrimci-Ozguven; Sung-Wan Kim; Paul Bergmans; Irina Usankova; Katalin Pungor
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-25

10.  Mismatch Negativity Indices as a Prognostic Factor for Remission in Schizophrenia.

Authors:  Ji Sun Kim; Young Joon Kwon; Hwa Young Lee; Ho-Sung Lee; Sungkean Kim; Se-Hoon Shim
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-02-29       Impact factor: 2.582

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.